Ann: Appendix 4C and Quarterly Update, page-52

somewhere above you mentioned a probability of a credit raise.

they are due to get a rebate for R&D (last year was 720k)
they are due for payment 1 from MND in next qtr (220k I think)
Epichem still profitable (farewell Colin)
We don’t know if a vet deal will or won’t land

so while I do share some concerns about the funds given the volume of activity ahead, I am fairly confident the current SP is not getting them all jittery about doing just that. Lots of variables and none the least of which was they just did a CR with the options. If they needed more cash then maybe they should have gone for 2c or 1 for every 3 shares held etc.

I just don’t think they want to credit raise if they don’t need to given the opportunities for some commercial deal in front of us.

just my thinking.